Momenta Ventures Invests in IoT Connectivity Company Thingstream
29.10.2019 13:00:00 EET | Business Wire | Press release
Thingstream, a leading provider of IoT Connectivity-as-a-Service, announces an investment from Momenta Ventures, a Digital Industry venture investment firm.
With Thingstream successfully separating from its incubating company Myriad Group earlier this year, Momenta Ventures’ investment marks a significant milestone to scale growth. “We are happy to have Momenta Ventures on-board. Their deep industry knowledge about Digital Industry and their commitment to Low Power, Wide Area Networks (LPWAN) is unique. Momenta’s investment in Thingstream is a significant affirmation of our mission to connect the enterprise via LPWAN, unlocking the potential of IoT”, says Philipp Bolliger, CEO Thingstream.
Thingstream offers simple to use connectivity solutions, supporting asset tracking, remote monitoring and related Industrial IoT use cases. Its solutions support low-power, secure connectivity with coverage across more than 190 countries. Thingstream’s holistic approach to connectivity accelerates enterprise projects by removing common barriers to collecting data from IoT devices thus unlocking the promise of IoT for enterprise customers worldwide. Thingstream supports connectivity through license spectrum cellular technologies today and are in the process of adding unlicensed LPWAN technologies including LoRaWAN to their offering.
Momenta Ventures’ Managing Director Ken Forster states “We’re excited to be supporting Thingstream in their journey to connect industrial devices world-wide. As practitioners in Digital Industry, we see reliable, low-cost connectivity as a critical enabler for enterprise IoT solutions. We believe that ubiquitous LPWAN devices, networks and applications, across licensed and unlicensed spectrum, will drive dramatic growth in scope and volume in the next few years.” Mr. Forster continues, “We believe our investment in Thingstream will further accelerate this LPWAN trend in Digital Industry, thus complementing our other ecosystem investments”.
Thingstream is preparing for a Series A investment and will be exhibiting at the premier event for the Industrial IoT: IoT Solutions World Congress in Barcelona (29-31 October), where they plan to make several key industry announcements.
About Thingstream
Thingstream is a leading provider of Connectivity-as-a-Service for the Internet of Things (IoT) applications. Thingstream’s intelligent Global Connectivity Platform provides low power, low cost, ubiquitous IoT connectivity via MQTT and works in over 190 countries already today. The secure, out-of-the-box IoT connectivity solution leverages both the globally-available GSM network as well as private LoRaWAN implementation to offer immediate, global IoT connectivity that no other low power connectivity provider can today. Thingstream specialises in helping simplify IoT connectivity, reducing costs and operational overheads in the delivery of an intelligent network of connected things. For more information visit https://thingstream.io.
About Momenta Ventures
Momenta Ventures is the investment arm of Momenta Partners, the leading Digital Industry Growth Partner firm. Led by deep operating practitioners with strong entrepreneurial and corporate track-records, Momenta Ventures has made over 30 investments with notable exits to SAP, PTC and Husqvarna Group. Momenta Ventures runs two Digital Industry ecosystem funds, focused on seed and Series A investments in Digital Energy, Manufacturing, Smart Spaces and Supply Chain globally. The most recent fund focuses on Digital Industry innovation powered by LPWAN, specifically LoRa and LoRaWAN. For more information visit https://momenta.vc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191029005492/en/
Contact information
Press contact for Thingstream:
Dan Walsh
MUSTARD PR
dan@mustardpr.com
+44 (0) 7827 816 971
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom